IN8bio (INAB) CFO receives 56,250 employee stock options at $1.58 strike price

Rhea-AI Filing Summary

IN8bio, Inc. reported that its Chief Financial Officer, Patrick McCall, received an employee stock option grant for 56,250 options to buy common stock at an exercise price of $1.58 per share. Following this grant, he holds 56,250 derivative securities directly.

The option vests in four equal parts, with 25% of the shares vesting on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, as long as he continues providing service through each vesting date. The option expires on May 9, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McCall Patrick

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	56,250	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 56,250 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options Granted: 56,250 options Exercise Price: $1.58 per share Post-transaction derivative holdings: 56,250 derivative securities +2 more

5 metrics

Options Granted 56,250 options Employee stock option grant to CFO on May 9, 2026

Exercise Price $1.58 per share Strike price for 56,250 options

Post-transaction derivative holdings 56,250 derivative securities Total options held directly after grant

Vesting installments 25% on four dates Vesting on Nov 9, 2026; May 9, 2027; Nov 9, 2027; May 9, 2028

Option Expiration May 9, 2036 Expiry date of employee stock option grant

Key Terms

Employee Stock Option, exercise price, vest, derivative securities, +1 more

5 terms

Employee Stock Option financial

"Employee Stock Option (right to buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

exercise price financial

"conversion_or_exercise_price: "1.5800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"shares subject to the option shall vest on each of November 9, 2026"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

derivative securities financial

"total_shares_following_transaction: "56250.0000" (derivative)"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCall Patrick

(Last) (First) (Middle)

C/O IN8BIO, INC.

350 5TH AVE. SUITE 5330

(Street)

NEW YORK NEW YORK 10118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IN8BIO, INC. [ INAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.58	05/09/2026		A		56,250		(1)	05/09/2036	Common Stock	56,250	$0	56,250	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date.

	/s/ William Ho, Attoney-in-Fact	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did IN8bio (INAB) disclose about CFO Patrick McCall’s latest equity award?

IN8bio disclosed that CFO Patrick McCall received an employee stock option grant for 56,250 shares at a $1.58 exercise price. These options are a compensation award, not an open-market purchase, and increase his potential ownership if the options eventually vest and are exercised.

How many stock options did IN8bio (INAB) grant to its CFO and at what price?

IN8bio granted CFO Patrick McCall 56,250 employee stock options with an exercise price of $1.58 per share. This means he can buy up to 56,250 IN8bio common shares at $1.58 if the options vest and are exercised before expiration.

What is the vesting schedule for Patrick McCall’s IN8bio (INAB) stock options?

The 56,250 stock options vest in four equal installments of 25% each. Vesting dates are November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, contingent on McCall continuing to provide service through each vesting date.

When do the newly granted IN8bio (INAB) stock options to the CFO expire?

The employee stock options granted to CFO Patrick McCall expire on May 9, 2036. He can only exercise vested portions of the 56,250 options before that date; any unexercised options after the expiration date will lapse and become worthless.

Are Patrick McCall’s new IN8bio (INAB) options a market purchase of shares?

No, the Form 4 shows a grant of employee stock options, not a market purchase. The transaction code is “A” for a grant or award, so McCall acquired the right to buy 56,250 shares at $1.58, subject to future vesting and exercise.